company background image
PEAR

Pear Therapeutics NasdaqCM:PEAR Stock Report

Last Price

US$1.85

Market Cap

US$258.2m

7D

-6.6%

1Y

-80.1%

Updated

01 Dec, 2022

Data

Company Financials +
PEAR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

PEAR Stock Overview

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines.

Pear Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pear Therapeutics
Historical stock prices
Current Share PriceUS$1.85
52 Week HighUS$14.60
52 Week LowUS$1.34
Beta0
1 Month Change-32.73%
3 Month Change5.71%
1 Year Change-80.07%
3 Year Changen/a
5 Year Changen/a
Change since IPO-80.85%

Recent News & Updates

Recent updates

Shareholder Returns

PEARUS Healthcare ServicesUS Market
7D-6.6%1.8%1.5%
1Y-80.1%-43.6%-14.8%

Return vs Industry: PEAR underperformed the US Healthcare Services industry which returned -47.9% over the past year.

Return vs Market: PEAR underperformed the US Market which returned -18.9% over the past year.

Price Volatility

Is PEAR's price volatile compared to industry and market?
PEAR volatility
PEAR Average Weekly Movement17.6%
Healthcare Services Industry Average Movement10.3%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: PEAR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: PEAR's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2013260Corey McCannhttps://peartherapeutics.com

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular.

Pear Therapeutics, Inc. Fundamentals Summary

How do Pear Therapeutics's earnings and revenue compare to its market cap?
PEAR fundamental statistics
Market CapUS$258.15m
Earnings (TTM)-US$30.37m
Revenue (TTM)US$11.45m

22.5x

P/S Ratio

-8.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PEAR income statement (TTM)
RevenueUS$11.45m
Cost of RevenueUS$8.09m
Gross ProfitUS$3.36m
Other ExpensesUS$33.73m
Earnings-US$30.37m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.22
Gross Margin29.38%
Net Profit Margin-265.26%
Debt/Equity Ratio52.5%

How did PEAR perform over the long term?

See historical performance and comparison